A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis

Completed · Phase 3

Conditions studied: Psoriasis

In brief

To detect onset of activity of ixekizumab in participants with moderate-to-severe plaque psoriasis and to document the same using sequential photographic images.

Key facts

Study ID

NCT02387801

Run by

Eli Lilly and Company

People needed

12

Starts

2015-04-01

Expected to finish

2016-08-01

Last updated by the study team

2019-09-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Present with chronic moderate-to-severe plaque psoriasis based on a confirmed (by a dermatologist) diagnosis of chronic plaque psoriasis for at least 6 months prior to baseline
• Active psoriatic skin lesions of plaque psoriasis (Ps)
• Are a candidate for phototherapy and/or systemic therapy
• Men must agree to use a reliable method of birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment
• Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment

You may not qualify if…

• Are unable to commit to the photography schedule for the duration of the study
• Have participated in any study with interleukin 17 (IL-17) or (IL-23) antagonists, including ixekizumab
• Serious disorder or illness other than psoriasis
• Serious infection within the last 3 months
• Breastfeeding or nursing (lactating) women

Where it is running

• Mount Sinai School of Medicine Dermatology Clinical Trials — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.